The effect of 6-day subcutaneous glucose-dependent insulinotropic polypeptide infusion on time in glycaemic range in patients with type 1 diabetes: a randomised, double-blind, placebo-controlled crossover trial

What Was Tested

This randomized controlled trial paper looks at GIP (Gastric Inhibitory Polypeptide).

The researchers previously reported a glucagonotropic effect of exogenous glucose-dependent insulinotropic polypeptide (GIP) during insulin-induced hypoglycaemia in individuals with type 1 diabetes.

Here the researchers investigate the effect of a 6-day s.c.

GIP infusion on time in glycaemic range as assessed by continuous glucose monitoring (CGM) in individuals with type 1 diabetes.

Why It Was Studied

The study was funded by grants from The Leona M. and Harry B.

Helmsley Charitable Trust and Aase og Ejnar Danielsens Fond.

Who Took Part

The abstract describes 20 men taking part.

PubMed indexes the participants as teenagers, young adults, adults, middle-aged adults and older adults, men only.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

The men were allocated by chance, so the GIP (Gastric Inhibitory Polypeptide) group and the comparison group should start out alike.

As a double-blind GIP (Gastric Inhibitory Polypeptide) study, the assignments were hidden from both participants and investigators until the end.

Some men received a placebo instead of GIP (Gastric Inhibitory Polypeptide), giving a reference point.

In the crossover set-up each of the men took both GIP (Gastric Inhibitory Polypeptide) and the comparison in turn, acting as their own control.

The primary outcome was glycaemic time below range, time in range and time above range.

What Was Measured

PubMed files the paper under topics including Blood Glucose, Body Mass Index, C-Peptide, Diabetes Mellitus, Type 1, Gastric Inhibitory Polypeptide, Gastrointestinal Agents and Glycated Hemoglobin.

Author keywords: Adipose tissue, Continuous glucose monitoring, GIP, Glucose-dependent insulinotropic polypeptide, Glycaemic control and Glycaemic time in range.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of GIP (Gastric Inhibitory Polypeptide) in 20 men.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2021 (Diabetologia), a journal based in Germany.

More context: the GIP (Gastric Inhibitory Polypeptide) compound page, all human trials.